1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NIDA SBIR/STTR Programs (Digital Health Technologies to Address the Social Determinants of Health in context of SUDs) is sponsored by National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH). NIDA's SBIR/STTR programs have a specific interest in digital health technologies to address social determinants of health in the context of Substance Use Disorders (SUDs).
This includes developing innovative technologies targeting SUDs, which aligns with behavioral health technology app innovation.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: U.S. small businesses developing innovative technologies relevant to substance use disorders. Confirm the full requirements in the official notice before applying.
Applications for NIDA SBIR/STTR Programs (Digital Health Technologies to Address the Social Determinants of Health in context of SUDs) are due April 5, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
NIDA SBIR/STTR Programs (Digital Health Technologies to Address the Social Determinants of Health in context of SUDs) is funded by National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Pilot and Feasibility Studies in Preparation for Substance Use and HIV Prevention Intervention and Services Research Trials (R34 Clinical Trial Optional) is sponsored by National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH). Supports pilot and feasibility studies (using an R34 mechanism) to develop and test interventions or service research frameworks addressing substance use and HIV prevention.
Mechanism for Time-Sensitive Substance Use Research (R21 Clinical Trial Optional) is sponsored by National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH). This funding opportunity invites applications addressing urgent research needs in substance use epidemiology and health services, including pilot studies on emerging drug issues, unexpected prescription drug abuse trends, and timely medical system challenges.
NIDA Core "Center of Transformative Science" Grant Program is sponsored by National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH). NIDA supports Core Centers of Transformative Science Grants to bring together investigators funded by NIH or other sources to enhance research relevant to substance use, addiction, and HIV.
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleNICHD forecast RFA-HD-28-005 (CAPSTONE), RFA-HD-28-006 (Learning Disabilities Research Centers), and RFA-HD-28-001 (Discovery Gateway) on October 20, 2026. All three are due around October 1, 2027. Here is what the incumbents hold and how challengers should prepare.
Read articleOn November 2, 2026, NIH released NOT-OD-27-006, a draft update to its Policy for Data and Safety Monitoring. As summarized by Harvard's research integrity office, the draft would extend risk-based monitoring from clinical trials to all NIH-supported clinical research, drop the blanket DSMB requirement for Phase 3 and multi-site trials, and require an NIH-approved monitoring plan scaled to risk, effective for applications six months after the final policy. Comments are due January 6, 2027. What it changes and how to respond.
Read article